Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) climbed roughly 4% following a disclosed purchase by co-chief executive officer Robert Duggan. According to a Securities and Exchange Commission filing, Duggan acquired 3.81 million shares of the company's common stock on June 12 at a price of $13.12 per share. The filing records the transaction as a private purchase.
After the purchase, the filing indicates Duggan directly owns 573.88 million shares of Summit Therapeutics. The filing also classifies him as a 10% owner of the company based on that direct holding.
In addition to Duggan's direct stake, the SEC document lays out a set of indirect holdings tied to family trusts and relationships. The filing lists 25.82 million shares held by the Mahkam Zanganeh Revocable Trust, with Duggan’s spouse identified as trustee, and 10.2 million shares held in the Shaun Zanganeh Irrevocable Trust, also with his spouse serving as trustee. The filing further identifies 76,680 shares owned by an immediate family member of his spouse and 31,000 shares held directly by his spouse.
The filing states that Duggan disclaims beneficial ownership of the indirectly held securities except to the extent of any pecuniary interest. No other transactions, price changes, or intentions were disclosed in the filing beyond the purchase date, share quantity, and price per share.
Context and market reaction
Market participants responded to the filing with a modest uptick in the stock price, with Summit Therapeutics shares increasing approximately 4% following the reported purchase. The SEC filing is the primary source for the transaction and the related ownership breakdown.
What the filing details and what it does not
- The filing specifies the date, share count, and purchase price for the private transaction.
- It provides a breakdown of direct and indirect holdings affiliated with Duggan and family-related trusts.
- The filing includes Duggan's disclaimer regarding beneficial ownership of indirectly held securities, noting he disclaims ownership except to the extent of any pecuniary interest.
No additional claims, intentions for future purchases or sales, or explanatory statements by company officers were included in the filing.